Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Position Lessened by Duality Advisers LP

Duality Advisers LP trimmed its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 34.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,197 shares of the biopharmaceutical company’s stock after selling 5,915 shares during the period. Duality Advisers LP’s holdings in Alnylam Pharmaceuticals were worth $1,673,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. ANTIPODES PARTNERS Ltd raised its holdings in shares of Alnylam Pharmaceuticals by 69.1% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 189,141 shares of the biopharmaceutical company’s stock worth $36,203,000 after acquiring an additional 77,307 shares in the last quarter. Vanguard Group Inc. raised its holdings in Alnylam Pharmaceuticals by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock valued at $2,286,181,000 after buying an additional 287,064 shares in the last quarter. Robeco Institutional Asset Management B.V. raised its holdings in Alnylam Pharmaceuticals by 155.7% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 12,513 shares in the last quarter. Quattro Financial Advisors LLC raised its holdings in Alnylam Pharmaceuticals by 2,517.8% during the first quarter. Quattro Financial Advisors LLC now owns 5,000 shares of the biopharmaceutical company’s stock valued at $747,000 after buying an additional 4,809 shares in the last quarter. Finally, Westpac Banking Corp raised its holdings in Alnylam Pharmaceuticals by 59.8% during the fourth quarter. Westpac Banking Corp now owns 1,512 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 566 shares in the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ALNY. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Monday, April 8th. Needham & Company LLC lifted their target price on Alnylam Pharmaceuticals from $200.00 to $275.00 and gave the stock a “buy” rating in a research report on Monday, June 24th. Morgan Stanley lifted their target price on Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the stock an “equal weight” rating in a research report on Friday. Barclays lifted their target price on Alnylam Pharmaceuticals from $236.00 to $291.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 25th. Finally, Royal Bank of Canada lifted their target price on Alnylam Pharmaceuticals from $235.00 to $250.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 25th. Eight investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $253.55.

Alnylam Pharmaceuticals Trading Up 0.7 %

Shares of ALNY stock traded up $1.88 on Friday, hitting $262.90. The stock had a trading volume of 644,465 shares, compared to its average volume of 886,082. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $263.73. The firm has a market cap of $33.25 billion, a P/E ratio of -98.13 and a beta of 0.37. The company has a fifty day moving average price of $178.94 and a two-hundred day moving average price of $169.02.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.23. The firm had revenue of $494.33 million during the quarter, compared to analyst estimates of $428.01 million. During the same period last year, the firm earned ($1.40) EPS. Alnylam Pharmaceuticals’s quarterly revenue was up 54.8% on a year-over-year basis. On average, analysts expect that Alnylam Pharmaceuticals, Inc. will post -3.92 earnings per share for the current year.

Insider Activity

In other news, Director Amy W. Schulman sold 21,700 shares of the business’s stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total value of $3,224,620.00. Following the completion of the transaction, the director now owns 8,436 shares of the company’s stock, valued at approximately $1,253,589.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, Director David E. I. Pyott sold 32,450 shares of the firm’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $220.69, for a total value of $7,161,390.50. Following the completion of the transaction, the director now owns 136 shares in the company, valued at approximately $30,013.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Amy W. Schulman sold 21,700 shares of the firm’s stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total value of $3,224,620.00. Following the completion of the transaction, the director now owns 8,436 shares of the company’s stock, valued at approximately $1,253,589.60. The disclosure for this sale can be found here. Insiders sold 67,357 shares of company stock valued at $13,436,711 in the last quarter. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.